Skip to main content

Table 4 Training data set results a

From: Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria

Tumor pathologic variables Receptors (core biopsy) Pretreatment hemoglobin parameters Sensitivity (%)/specificity (%) PPV (%)/NPV (%) AUC (%) (95% CI)
IDC/ILC, NS, MC    76.2/74.3 65.7/83.1 76.9 (59.60; 95.46)
IDC/ILC, NS, MC TN, HER2, ER   71.1/80.7 70.5/81.6 87.1 (71.54; 98.63)
   tHb 58.1/84.5 69.9 /75.9 76.7 (53.01; 96.64)
   oxyHb 52.9/86.1 71.5/73.8 76.8 (54.60; 94.34)
   deoxyHb 59.3/81.8 68.1/75.9 67.4 (40.97; 90.09)
   tHb, oxyHb 60.3/87.9 77.1/77.5 78.6 (55.46; 97.08)
   tHb, deoxyHb 64.1/85.2 74.3/78.5 74.6 (55.58; 97.31)
IDC/ILC, NS, MC TN, HER2, ER tHb 80.5/87.6 80.8/87.5 92.9 (82.76; 99.70)
IDC/ILC, NS, MC TN, HER2, ER oxyHb 79.9 /91.4 85.2/87.9 96.1 (88.91; 100.0)
IDC/ILC, NS, MC TN, HER2, ER deoxyHb 73.0/82.0 72.9/82.9 88.9 (74.94; 98.94)
IDC/ILC, NS, MC TN, HER2, ER tHb, oxyHb 92.5/95.2 92.5/95.2 98.2 (93.68; 100.0)
IDC/ILC, NS, MC TN, HER2, ER tHb, deoxyHb 83.9/87.2 80.7/89.7 95.1 (86.94; 99.75)
  1. aCI, confidence interval; deoxyHb, Deoxygenated hemoglobin; ER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; IDC, Invasive ductal carcinoma; IDC/ILC, Invasive mammary carcinoma with mixed ductal and lobular features; ILC, Invasive lobular carcinoma; MC, Mitotic count; NS, Nottingham score; oxyHb, Oxygenated hemoglobin; NPV, Negative predictive value; PPV, Positive predictive value; tHb, Total hemoglobin; TN, Triple-negative.